| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da5792b829d5c4a5aa8a9efbf828b7e4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07b05f7e7e36c005ce6de824e89b595c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93aae15d51b09018a59ab753700326c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c2efc1a02ae5d45db6f3a8877629c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7f47d012f1e79840ea45642e25f88c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60fe4aeaf69a4af5c873186facbddff4 |
| publicationDate |
2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0414174-B1 |
| titleOfInvention |
Antigen-binding antibodies or fragments of the same use thereof, polynucleotide, vector, expression system, and pharmaceutical composition. |
| abstract |
"nogo-a binding molecules and their pharmaceutical use". The present invention provides a binding molecule that is capable of binding to a human nogoa polypeptide, or human nig, or human nig-d20 or human nogoa_342-357 with a dissociation constant <1000 nm, a polypeptide encoding this binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of production and a binding molecule; an isolated host cell comprising an expression system as defined above; the use of such a binding molecule as a pharmaceutical especially for nerve repair treatment; a pharmaceutical composition comprising said molecule; and a method for treating diseases associated with nerve repair. |
| priorityDate |
2003-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |